NDAORALCAPSULE
Approved
Dec 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EMCYT (estramustine phosphate sodium) is an oral small-molecule chemotherapy combining an estrogen with a nitrogen mustard alkylator, designed to deliver cytotoxic activity directly to prostate cancer cells. It is indicated for metastatic and progressive prostate cancer in patients who have not responded to or tolerated other therapies. The drug works by binding to microtubule-associated proteins and disrupting cell division.
$0.043BPart D
LOE ApproachingDeclining
Minimal commercial activity with only 44 Part D claims in 2023 signals a legacy product with very small patient base and shrinking team resources.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Roles linked to EMCYT are extremely limited (0 active postings identified), reflecting the product's minimal market footprint and legacy status. Working on this product offers little visibility, learning, or career advancement potential in modern pharma.
Regional Sales ManagerAccount Manager
Worked on EMCYT at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.